I was thinking about the trials a little bit this morning. Since different parts of the country may have different strains of the virus with different morbidities and mortalities, I hope the 2-1 randomization is also with regards to individual sites, not just the trial overall. You don't want more of either group represented by NYC patients, for example, who may have a worse strain. This is particularly important with the mild to mod trial since there are only 75 patients overall.

Also, I wonder if the lab values will be randomized also. The reason for this is if there is a sudden reversion to the normals for all lab values in 2/3 of patients at day 3, then Dr. Patterson and all site investigators will know who is getting leronlimab at that point regardless of clinical progression of the patients.